Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118358 · ClinicalTrials.gov registry record · NA
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
A NA study, sponsored by Biotronik.
- Recruiting
- Registry status
- NA
- Development phase
- 325
- Enrollment target
NCT07118358: Recruiting NA study, sponsored by Biotronik.
NCT07118358 is a NA study that is actively recruiting participants, run by Biotronik. The registered enrollment target is 325 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07118358, a NA study, is actively recruiting participants, sponsored by Biotronik.
- RECRUITING
- Registry status
- NA
- Development phase
- 325 participants
- Enrollment target
Study Summary
The objective of this Investigational Device Exemption trial is to confirm the safety and performance of the LivIQ leadless pacemaker system, in patients with a Class I or II indication for ventricular pacing (VVI/VDD) according to applicable guidelines. An integrated atrioventricular synchrony sub-study (AVS) is specifically designed to evaluate the AVS performance of the LivIQ system.
Primary Outcome
Demonstrate that the freedom from SADEs related to the LivIQ system and/or procedure through 3-month follow-up exceeds the performance goal.
Interventions
- DEVICE LivIQ Leadless Pacemaker System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT07118358 shows while recruiting
NCT07118358 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which LivIQ Leadless Pacemaker System is the first listed.
NCT07118358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07118358 about?
NCT07118358 is a clinical study titled "BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System". The objective of this Investigational Device Exemption trial is to confirm the safety and performance of the LivIQ leadless pacemaker system, in patients with a Class I or II indication for ventricular pacing (VVI/VDD) according to applicable guidelines. An integrated atrioventricular synchrony sub-...
What is the current status of trial NCT07118358?
This trial is currently recruiting. It is a NA study. The enrollment target is 325 participants. The study started on 2026-03-16. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07118358?
The interventions under investigation include: LivIQ Leadless Pacemaker System (DEVICE).
Who is sponsoring clinical trial NCT07118358?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07118358's enrollment target sits among peer trials
325 311th of 2000 higher than 1,689 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI